stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Gross margin
argenex SE's gross margin over the twelve months to 30 September 2026 was 90.2%, up 0.8 percentage points from fiscal 2025 (89.4%). Over the past ten years it has ranged from 89.4% (fiscal 2025) to 100.0% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 89.4% | (0.52) |
| FY2024 | 89.9% | (0.80) |
| FY2023 | 90.7% | (2.68) |
| FY2022 | 93.4% | (6.61) |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 0.00 |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 90.6% | (0.02) |
| Jun 2026 | 90.6% | (0.18) |
| Mar 2026 | 90.8% | 2.09 |
| Dec 2025 | 88.7% | (1.84) |
| 25 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| RVMD Revolution Medicines, Inc. compare | 95.6% |
| GMAB Genmab A/S Sponsored ADR compare | 93.0% |
| INCY Incyte Corporation compare | 92.7% |
| ARGX argenex SE | 90.2% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 89.4% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 85.8% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| MRNA Moderna, Inc. compare | 23.4% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement